Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rebif Ready For Antegren Following MS Market Share Gains, Serono Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Serono is confident that Rebif can compete against Elan/Biogen Idec's Antegren both on mechanism of action and indication; Antegren's estimated user fee deadline is in November. Rebif gains share against Biogen Idec's Avonex and Berlex' Betaseron, reaching 12-month rolling sales of $1 bil.

You may also be interested in...



Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.

Elan/Biogen Idec's Tysabri, Formerly Antegren, Approved For MS Based On One-Year Data

Monoclonal antibody's label includes studies as monotherapy and as add-on in patients previously treated with Avonex. Two-year results are expected in the first half of 2005.

Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says

The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel